NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® WAS WELL-TOLERATED FOR MORE THAN 8 YEARS Market News
Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy Pharmaceutical Investing
Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Life Science Investing
Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program Company News
Children with Chronic Graft Versus Host Disease May Now Be Prescribed IMBRUVICA® Pharmaceutical Investing
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® Market News
Health Canada Approves OPDIVO® with Chemotherapy as Neoadjuvant Treatment for Adult Patients with Resectable Non-Small Cell Lung Cancer Pharmaceutical Investing
AMGEN TO PRESENT NEW DATA AT ESC CONGRESS 2022 HIGHLIGHTING UP TO 8.5 YEARS OF REPATHA® SAFETY AND TOLERABILITY DATA IN HIGH-RISK ASCVD PATIENT POPULATIONS Market News
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022 Pharmaceutical Investing
Gilead Announces First Global Regulatory Approval of Sunlenca® , the Only Twice-Yearly HIV Treatment Option Pharmaceutical Investing
Ginkgo Bioworks Announces Strategic Purchase of Epidemiological Data Infrastructure Assets Company News
